Fulcrum Therapeutics's top three insider shareholders as of June 09, 2026 are Capital Management, L.P. Ra (TenPercentOwner, 11.61Mn shares), Capital Management, L.P. Ra (TenPercentOwner, 6.05Mn shares), Mark J Levin (Director, 3.96Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Mark J Levin | - | 0 | 3,962,202 | 12 Nov, 2021 |
| Capital Management, L.P. Ra | - | 0 | 11,609,704 | 24 Jan, 2023 |
| Rock Ventures Iii, L.P. Third | - | 1,962,202 | 0 | 15 Dec, 2022 |
| Robert J Gould | Interim President Ceo | 454,864 | 0 | 04 Feb, 2026 |
| Alex Sapir | - | 193,360 | 0 | 08 Jul, 2024 |
| Curtis Gale Oltmans | Chief Legal Officer | 10,252 | 0 | 17 Dec, 2025 |
| Christopher Moxham | Chief Scientific Officer | 31,071 | 0 | 12 Aug, 2021 |
| Greg Tourangeau | Principal Accounting Officer | 14,062 | 0 | 09 May, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 02 Feb, 2026 | Greg Tourangeau | Stock Option (right to buy) | A | 57,000 | $0.00 | 57,000 | D | A |
| 02 Feb, 2026 | Alex Sapir | Stock option - Right to Buy | A | 650,000 | $0.00 | 650,000 | D | A |
| 02 Feb, 2026 | Curtis Gale Oltmans | Stock Option (right to buy) | A | 170,000 | $0.00 | 170,000 | D | A |
| 02 Feb, 2026 | Robert J Gould | Common Stock | D | 15,000 | $10.72 | 454,864 | D | S |
| 02 Feb, 2026 | Curtis Gale Oltmans | Stock Option (right to buy) | A | 170,000 | $0.00 | 170,000 | D | A |
| 02 Jan, 2026 | Robert J Gould | Common Stock | D | 15,000 | $10.87 | 469,864 | D | S |
| 02 Feb, 2026 | Alex Sapir | Stock option - Right to Buy | A | 650,000 | $0.00 | 650,000 | D | A |
| 02 Feb, 2026 | Greg Tourangeau | Stock Option (right to buy) | A | 57,000 | $0.00 | 57,000 | D | A |
| 02 Jan, 2026 | Robert J Gould | Common Stock | D | 15,000 | $11.87 | 469,864 | D | S |
| 15 Dec, 2025 | Curtis Gale Oltmans | Common Stock | D | 3,452 | $12.92 | 10,252 | D | S |
| 15 Dec, 2025 | Curtis Gale Oltmans | Common Stock | D | 3,452 | $12.92 | 10,252 | D | S |
| 08 Dec, 2025 | Capital Management, L.P. Ra | Common Stock | D | 1,377,020 | $13.33 | 8,852,079 | I | S |
| 08 Dec, 2025 | Capital Management, L.P. Ra | Common Stock | D | 2,706,397 | $14.28 | 6,145,682 | I | S |
| 08 Dec, 2025 | Capital Management, L.P. Ra | Common Stock | D | 91,722 | $14.98 | 6,053,960 | I | S |
| 19 Nov, 2025 | Robert J Gould | Common Stock | D | 15,000 | $11.03 | 484,864 | D | S |
| 26 Jun, 2025 | Kate Haviland | Stock Option (right to buy) | A | 36,000 | $0.00 | 36,000 | D | A |
| 26 Jun, 2025 | Robert J Gould | Stock Option (right to buy) | A | 36,000 | $0.00 | 36,000 | D | A |
| 26 Jun, 2025 | Katina Dorton | Stock Option (right to buy) | A | 36,000 | $0.00 | 36,000 | D | A |
| 26 Jun, 2025 | Sonja Banks | Stock Option (right to buy) | A | 36,000 | $0.00 | 36,000 | D | A |
| 26 Jun, 2025 | Kate Haviland | Stock Option (right to buy) | A | 36,000 | $0.00 | 36,000 | D | A |